![Nigel McCracken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nigel McCracken
Directeur des opérations chez
VIRAX BIOLABS GROUP LIMITED
Fortune : 7 447 $ au 30/06/2026
Profil
Nigel McCracken currently works at Virax Biolabs Group Ltd., as Chief Operating Officer & Director.
Dr. McCracken also formerly worked at Debiopharm International SA, as Executive Director & VP-Translational Medicine from 2014 to 2019, NuCana Plc, as COO, Senior VP-Discovery & Early Development, and BerGenBio ASA, as Chief Scientific Officer from 2021 to 2023.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and graduate degree from King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/07/2026 | 2 533 ( 0,32 % ) | 7 447 $ | 30/06/2026 |
Postes actifs de Nigel McCracken
| Sociétés | Poste | Début |
|---|---|---|
| VIRAX BIOLABS GROUP LIMITED | Directeur des opérations | 01/09/2023 |
Anciens postes connus de Nigel McCracken
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOINVENT ASA | Directeur Technique/Scientifique/R&D | 01/09/2023 |
Debiopharm International SA
 Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Directeur/Membre du Conseil | 01/04/2019 |
| NUCANA PLC | Directeur des opérations | - |
Formation de Nigel McCracken
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Health Technology |
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Virax Biolabs Group Ltd.
 Virax Biolabs Group Ltd. Financial ConglomeratesFinance Develops and distributes immunology software, platform and medical devices | Finance |
